GSK: stock down after Q3 results.

(CercleFinance.com) - The GSK (GlaxoSmithKline) share has slid 1.
5% in London today, after the group announced Q3 EPS that is up 49% at 24.8 pence, although adjusted EPS rose by just 3% at 32.5 pence.

The healthcare group improved its adjusted operating margin by one point to 31.5% on revenues that are up 4% to over 7.8 billion pounds, driven by the pharmaceuticals and consumer healthcare divisions, while vaccine sales were flat.

GSK's management is maintaining its target of adjusted EPS growth of between 3% and 5% at constant currencies over FY 2017, compared with a 2% increase posted since the beginning of the year.


Copyright (c) 2017 CercleFinance.com. All rights reserved.